Figure 2.

CBD prolongs survival mice bearing intracranial tumors derived from GSCs. Tumors were generated in female athymic nu/nu mice by the intracranial injection of 5 × 10³ cells (a) 3832 or (b) 387 luciferase-labeled cells in 4 μl of media. Treatments were started at day 9 following BLI confirmation of tumor presence (using IVIS Lumina) and randomization of mice. Starting on day 9, 15 mg/kg of CBD was administered intraperitoneally 5 days a week until completion of the experiment. Animal health was monitored daily and when mice showed signs of disease progression, they were humanely killed in accordance with institutional IACUC guidelines. Survival data was evaluated using Kaplan–Meier curves and a long-rank Mantel–Cox test. (c) Representative tumor sections represent inhibition of Ki67 (upper panel) staining, upregulation of cleaved caspase-3 (middle panel) and inhibition of p-AKT (lower panel) induced by CBD. Tumors were harvested 25 days after tumor induction. Bar=200 μm. (d) BLI measurements demonstrate initial response to CBD (reduction of tumor size at day 22), followed by tumor resistance to treatment 1 week later (day 29)